Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of <i>NTRK1</i>Matthew L. Hemming, Sandro Santagata, Ziming Du et al.|JCO Precision Oncology|2020Cited by 36
Molecular characterization and management of secondary resistance to serial TRK inhibitors.Michael J. Nathenson, George D. Demetri, Karan Malik et al.|Journal of Clinical Oncology|2019Cited by 1